Tokio Marine Asset Management Co. Ltd. lowered its stake in Core Laboratories (NYSE:CLB) by 7.8% during the first quarter, Holdings Channel reports. The fund owned 2,196 shares of the oil and gas company’s stock after selling 186 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Core Laboratories were worth $254,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the company. Genesee Valley Trust Co. increased its stake in shares of Core Laboratories by 0.3% in the first quarter. Genesee Valley Trust Co. now owns 5,538 shares of the oil and gas company’s stock worth $639,000 after buying an additional 16 shares in the last quarter. Integrated Investment Consultants LLC increased its stake in shares of Core Laboratories by 0.8% in the first quarter. Integrated Investment Consultants LLC now owns 2,330 shares of the oil and gas company’s stock worth $269,000 after buying an additional 19 shares in the last quarter. Cetera Advisors LLC increased its stake in shares of Core Laboratories by 0.7% in the third quarter. Cetera Advisors LLC now owns 3,611 shares of the oil and gas company’s stock worth $398,000 after buying an additional 24 shares in the last quarter. Creative Planning increased its stake in shares of Core Laboratories by 1.9% in the first quarter. Creative Planning now owns 1,730 shares of the oil and gas company’s stock worth $200,000 after buying an additional 33 shares in the last quarter. Finally, First Bank & Trust increased its stake in shares of Core Laboratories by 2.7% in the first quarter. First Bank & Trust now owns 1,411 shares of the oil and gas company’s stock worth $163,000 after buying an additional 37 shares in the last quarter.
Shares of Core Laboratories (NYSE:CLB) traded up 2.73% on Friday, reaching $108.67. The company had a trading volume of 455,265 shares. Core Laboratories has a 52-week low of $96.30 and a 52-week high of $133.38. The company has a 50 day moving average price of $111.82 and a 200 day moving average price of $113.71. The stock has a market capitalization of $4.80 billion, a PE ratio of 71.97 and a beta of 1.55.
Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, April 19th. The oil and gas company reported $0.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.03. Core Laboratories had a net margin of 10.74% and a return on equity of 65.65%. The business had revenue of $157.81 million for the quarter, compared to the consensus estimate of $150.44 million. During the same period in the prior year, the business posted $0.37 earnings per share. Core Laboratories’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts anticipate that Core Laboratories will post $2.21 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 23rd. Stockholders of record on Friday, April 28th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date is Thursday, April 27th. Core Laboratories’s dividend payout ratio (DPR) is presently 150.68%.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Mideast Time and is owned by of Mideast Time. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.mideasttime.com/tokio-marine-asset-management-co-ltd-sells-186-shares-of-core-laboratories-clb/1708710.html.
A number of equities research analysts have recently commented on the company. Scotiabank set a $136.00 price objective on Core Laboratories and gave the company a “hold” rating in a research report on Saturday, April 22nd. ABN Amro raised Core Laboratories to a “hold” rating in a research report on Friday, April 21st. Zacks Investment Research raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, April 21st. Loop Capital raised Core Laboratories from a “hold” rating to a “buy” rating and lifted their price objective for the company from $125.00 to $130.00 in a research report on Friday, April 21st. Finally, Tudor Pickering assumed coverage on Core Laboratories in a research report on Thursday, March 23rd. They issued a “hold” rating for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company’s stock. Core Laboratories currently has a consensus rating of “Hold” and an average target price of $125.60.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.